Veltuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP for 4 weeks in combination with 2 infusions of epratuzumab...